Search clinical trials for: intermediate risk

Total 15882 results

Phoenix Molecular Imaging

Completed

C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma

Prostate Cancer | Prostate Adenocarcinoma

United States
China National Center for Cardiovascular Diseases

Unknown

Risk Factors of Intermediate Coronary Lesion Progression

Coronary Angiography | Coronary Atheroscleroses

China
Weill Medical College of Cornell University
Sunesis Pharmaceuticals

Completed

Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy

Myelodysplastic Syndrome

United States
KU Leuven
Belgian Cancer Registry

Completed

Functional Outcomes and QoL in Patients With High Versus Low and Intermediate Risk Prostate Cancer Treated by RARP

Quality of Life | Prostate Cancer | Erectile Function | Urinary Function

Belgium
Daiichi Sankyo, Inc.

Withdrawn

DS-9231 in Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)

Pulmonary Embolism
Rigshospitalet, Denmark

Completed

The Effect of Frequency and Duration of Breaks in Sitting Time on Metabolic Cardiovascular Risk Factors (BPS2)

Sedentary Lifestyle | Overweight and Obesity | Metabolic Disease

Denmark
Sun Yat-sen University
Guilin Medical University, China; Fifth Affiliated Hospital, Sun Yat-Sen University and other collaborators

Unknown

Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era

Nasopharyngeal Carcinoma

China
Amgen

Completed

Darbepoetin Alfa MDS Companion Protocol

Myelodysplastic Syndrome (MDS)

Belgium
University of Southern California
National Cancer Institute (NCI)

Withdrawn

Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in Remission

Adult Acute Myeloid Leukemia in Remission | Childhood Acute Myeloid Leukemia in Remission

United States
Associazione Qol-one

Terminated

Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q

Myelodysplastic Syndromes

France, Italy, Greece
Helsinn Healthcare SA

Completed

Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Terminated

Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS

Myelodysplastic Syndromes

Italy
Children's Oncology Group
National Cancer Institute (NCI)

Withdrawn

Studying Body Mass Index in Younger Patients Who Are Receiving Treatment for High-Risk Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic Leukemia

United States
University of Maryland
Bristol-Myers Squibb

Completed

Belatacept in Renal Transplantation With Intermediate Risk Maryland Aggregate Pathology Index (MAPI) Scores

End-Stage Renal Disease

United States
University of Sao Paulo
Fundação de Amparo à Pesquisa do Estado de São Paulo

Completed

Prospective Study Comparing Extended With Limited Pelvic Lymphadenectomy in Intermediate and High Risk Prostate Cancer Patients Undergoing Radical Prostatectomy (LFD)

Prostate Cancer

Brazil
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)

Myelofibrosis

Italy, United States, Canada, Germany
Sunnybrook Health Sciences Centre

Unknown

A Phase II Trial of High Dose-Rate Brachytherapy as Monotherapy in Low and Intermediate Risk Prostate Cancer

Carcinoma of the Prostate

Canada
Assistance Publique Hopitaux De Marseille

Completed

Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes?

Acute Coronary Syndrome

France
Mansoura University

Completed

Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer (NMIBCIVT)

Carcinoma of Urinary Bladder, Superficial

Egypt
Novartis Pharmaceuticals

Withdrawn

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer (EarLEE-2)

Breast Cancer
Fundacio d'Investigacio en Atencio Primaria Jordi...
Preventive Services and Health Promotion Research Network

Completed

Improving Intermediate Risk Management. MARK Study (MARK)

Myocardial Infarction | Stroke | Peripheral Arterial Disease | Angina Pectoris

Spain
University of Sao Paulo General Hospital

Unknown

Analysis Between Coronary Angiotomography and Sensitive Troponin in Intermediate Risk of Acute Coronary Syndrome (CONECTTIN)

Chest Pain | Acute Coronary Syndrome

Brazil
Cancer Center of Irvine
SenoRx, Inc.

Completed

Use of the Contura™ Catheter in Intermediate-Risk, Pathological Stage 0, I, or II (Up to 3.0 cm) Breast Cancer Patients

Breast Cancer

United States
Fundación Canaria de Investigación Sanitaria
Hospital Universitario de Canarias

Unknown

Enzalutamide and External Beam Hypofractionated Radiotherapy For Intermediate Risk Localized Prostate Cancer (ENZART)

Prostate Carcinoma

Spain
Amgen

Completed

Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

MDS

Germany, Italy, Belgium, Czechia, Switzerland, France, Austria, Greece, Spain
Groupe Francophone des Myelodysplasies
Celgene

Completed

Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q (GFM-AZA-REV-09)

Myelodysplastic Syndromes

France
Novartis Pharmaceuticals

Terminated

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

Thrombocytopaenia

United States, Belgium, Australia, Canada, Hong Kong, Austria, Brazil, Czechia, Israel, Russian Federation, Spain, Sweden, Thailand, Denmark, France, Germany, Ireland, Italy, Korea, Republic of, Peru, Switzerland, Taiwan, Turkey, Hungary and more
Pharnext SA

Completed

Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A

Charcot-Marie-Tooth Disease | Hereditary Neuropathy With Liability to Pressure Palsies | Genetic Disorders

France
Julie E. Bauman, MD, MPH
AVEO Pharmaceuticals, Inc.

Terminated

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

Carcinoma, Squamous Cell of Head and Neck

United States
Wake Forest University Health Sciences
American Heart Association

Completed

Efficacy Evaluation of Observation Unit Cardiac Magnetic Resonance Imaging (MRI) in Patients With Intermediate Risk Acute Chest Pain

Chest Pain | Acute Coronary Syndrome

United States
The University of Texas Health Science Center at...
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer

Prostate Cancer

United States
Region Skane

Completed

MESS-study MRSA Eradication Study Skåne (MESS)

Throatcarriers of MRSA

Sweden
Ontario Clinical Oncology Group (OCOG)
Canadian Institutes of Health Research (CIHR); Trans Tasman Radiation Oncology...

Completed

PROFIT - Prostate Fractionated Irradiation Trial

Prostate Cancer

Canada, Australia, France
Onconova Therapeutics, Inc.

Completed

Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk

Myelodysplastic Syndrome

United States
Onconova Therapeutics, Inc.

Withdrawn

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Sunnybrook Health Sciences Centre
Celgene

Completed

Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS (REMMYDYS)

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic | Angiogenesis

Canada
Washington University School of Medicine
CTI BioPharma

Withdrawn

Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes | Myelofibrosis | Chronic Myelomonocytic Leukemia | Juvenile Myelomonocytic Leukemia | Myeloproliferative Neoplasm | Atypical Chronic Myeloid Leukemia
National Cancer Institute, Naples

Completed

ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment

Breast Cancer

Italy
International Consortium on Acute Leukemias

Unknown

Feasibility Study of Intermediate Doses of ARA-C With Autologous SCT as Consolidation of Low/Intermediate-risk AML (ICAML2015)

Acute Myeloid Leukemia

Brazil
Nantes University Hospital
Chugai Pharmaceutical; French Innovative Leukemia Organisation

Completed

Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk (LAM2006IR)

Acute Myeloid Leukemia

France
GlaxoSmithKline

Completed

Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke

Atrial Fibrillation | Fibrillation, Atrial

Spain, United States, Taiwan, Estonia, Canada, Sweden, Thailand, Germany, Korea, Republic of, Latvia, Romania, Argentina, Belgium, France, India, Netherlands, New Zealand, Italy, Norway, United Kingdom, Greece, Hungary, Denmark, Brazil, Mexic...
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation

Hematologic Malignancies

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Celgene Corporation

Terminated

A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients

Myelodysplastic Syndrome | MDS | Low to Intermediate-1 MDS | Non-deletion 5q

United States
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaborators

Completed

Action to Control Cardiovascular Risk in Diabetes (ACCORD) (ACCORD)

Cardiovascular Diseases | Coronary Disease | Hypertension | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Atherosclerosis | Hypercholesterolemia

United States, Canada
Groupe Francophone des Myelodysplasies
Roche Pharma AG; Celgene

Completed

Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.

Myelodysplastic Syndromes

France, Monaco
Meshalkin Research Institute of Pathology of Circulation

Unknown

Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary Embolism (PSCAT)

Pulmonary Embolism | Intermediate-high Risk | Combination of Oral Anticoagulation Therapy and Sildenafil

Russian Federation
Hospices Civils de Lyon

Unknown

Hyaluronic Acid for Hypofractionated Prostate Radiotherapy (RPAH1)

Prostate Cancer

France
Northwestern University

Unknown

Ulipristal for Endometriosis-related Pelvic Pain

Endometriosis

United States
Johnson & Johnson Pharmaceutical Research & Development...
Ortho Biotech Clinical Affairs, L.L.C.

Withdrawn

A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Anemia

Search clinical trials for: intermediate risk

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations